Compare the evidence across five entries.
Use this page to compare recovery peptides by the question being studied, the people or animals studied and the size of the uncertainty. It is a map of five guide entries, rather than a ranking of what belongs in your life.
Perform Peptide may earn money when readers become Promise patients.
Compare the evidence before the names
These entries sit near each other in recovery conversations, but their research does different jobs. A tendon experiment in rats, a short hormone study in healthy volunteers and a trial in adults with a specific disease cannot be treated as equivalent tests of recovery.
In the table, signal describes the biological idea researchers discuss. It does not mean an effect has been established for your circumstances. Follow an entry for the distinction between the substance itself, a related molecule and a combined preparation.
| Entry | Research thread | Evidence setting | Main limit |
|---|---|---|---|
| BPC-157 | Tissue-repair experiments | Mostly animals; limited small human reports | No established recovery benefit in controlled human injury trials |
| Wolverine | BPC-157 with TB-500 | Component and related-protein research | No controlled human recovery trial of the pair |
| CJC-1295 and ipamorelin | Different signals toward growth-hormone release | Small human component studies; blend unestablished | Hormone findings do not establish sleep or recovery benefit |
| Sermorelin | A growth hormone-releasing signal | Older medical uses; small adult studies | No current approved product or established adult recovery role |
| Tesamorelin | A growth hormone-releasing signal | Human trials in a specific HIV-related condition | Approved-product evidence is not general recovery evidence |
On a phone, scroll the table sideways to read every column.
The repair pair is not one established category
The BPC-157 rat-tendon work is relevant to a research question about an injured animal tendon. The small human reports do not provide the same kind of controlled evidence. They leave causation and long-term safety unresolved.
Wolverine adds TB-500 to BPC-157, but adding a component does not add a human trial. TB-500 is a short fragment of thymosin beta-4, a longer protein. The FDA’s assessment of TB-500 makes that distinction central. Human work on the longer protein cannot establish the fragment’s safety, much less the safety of the pair.
Three entries concern a hormone signal
Sermorelin, tesamorelin and the CJC-1295 and ipamorelin blend all involve signalling toward growth-hormone release. That shared pathway is a reason to compare questions about blood sugar, fluid retention and growth-related signals. It is not a reason to assume the products are interchangeable.
The small human CJC-1295 study concerned the DAC form, which has a chemical attachment that extends its time in the body. It measured hormones. A product described without DAC is a different ingredient, and a blend with ipamorelin introduces another evidence gap.
Sermorelin’s former approvals concerned testing and childhood growth problems. They were not adult sleep or recovery approvals. Tesamorelin’s human trial concerned excess abdominal fat in adults with HIV. Neither history establishes a recovery benefit for healthy performers.
Ask whether the outcome matches your question
If you want to understand sleep, a hormone measurement is only part of the question. If your concern is an injury, an experiment on a surgically cut rat tendon is only part of the question. If you see a story about a change in appearance, that does not answer a question about function.
There is no evidence-based winner across these five entries for the broad goal of recovery in otherwise healthy people. We leave the table unranked because the necessary comparisons have not been made. Personal accounts can explain interest in a compound, but they cannot fill that gap.
Access is another column, not a seal of approval
Promise Peptides lists these five options and has a licensed U.S. provider review every request. A reader may not qualify, and access depends on the state and treatment. We link to the corresponding listing without treating availability as evidence of benefit.
Compounded medicines are not FDA-approved. The FDA’s compounding explanation distinguishes a pharmacy preparation from an approved medicine. Ingredient eligibility and the restriction on copying biologics are additional questions; a product listing does not resolve them. The individual pages carry the limits relevant to each entry.
All five entries also raise anti-doping questions for tested athletes, independently of a medical review. The individual product guides link the 2026 prohibited list. A prescription is not, by itself, permission under sport rules.
The useful result of this comparison is a more precise question. You might want to ask about the actual substance, the people studied, a safety gap or the legal basis for a proposed product. You do not need a ranked shortlist to bring any of those questions into a clinical conversation.